help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 10, No. 8, 561-562, September 2005; doi:10.1634/theoncologist.10-8-561
© 2005 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Commentary

New Prescription Drug Benefit: The Role of the Oncologist

Jointly authored by officers of the American Society of Clinical Oncology and The CEO Roundtable On Cancer

Joseph S. Bailes, M.D., American Society of Clinical Oncology, PO Box 131599, The Woodlands, TX 77393-1599, USA. Telephone: 214-725-6100; Fax: 936-273-9385; e-mail: bailesj{at}houston.rr.com; and David R. Brennan, President, CEO, AstraZeneca L.P., U.S., 1800 Concord Pike, Wilmington, DE 19850, USA. Telephone: 302-886-4701; Fax: 302-886-1889; e-mail: nancy.herczeg{at}AstraZeneca.com

Increasingly, cancer drugs are being developed for oral self-administration, and those oral drugs are frequently among the most sought-after by oncologists and patients, as their targeted mechanisms offer the promise of greater effectiveness with fewer toxicities. It is quite timely, therefore, that the Medicare program on January 1, 2006, will launch a new prescription drug benefit to cover, for the first time, oral and other self-administered prescription drugs for cancer and other diseases. The new benefit, Part D, is clearly a positive development for cancer patients, but it introduces new complexity to the process of selecting and financing prescription drug coverage. Oncologists, like other physicians, should be prepared to advise their patients concerning options for coverage.

Key Words. Medicare • Part D • Prescription drug reimbursement • Benificiary




This article has been cited by other articles:


Home page
 The OncologistHome page
M. McClellan
Help Your Patients Become Aware of the New Medicare Prescription Drug Plans
Oncologist, September 1, 2005; 10(8): 563 - 564.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2005 by AlphaMed Press.